ONO-4232 / Ono Pharma - LARVOL DELTA

First Clinical Experience with ONO-4232: A Randomized, Double-Blind, Placebo-Controlled Healthy Volunteer Study of a Novel Lusitropic Agent for Acutely Decompensated Heart Failure. (PubMed) - Clin Ther - "In healthy adults ONO-4232 was generally well tolerated in the dose range of 0.001 to 0.27 ng/kg/min. There were dose-related changes in systolic blood pressure and heart rate. Infusion site erythema, which was likely associated with a venodilatory effect and possible evidence for the pharmacologic effects of ONO-4232, occurred increasingly with increasing dose. Pharmacokinetic parameters appeared to be dose-proportional. The study results support further evaluation of the cardiovascular effects of this first-in-class selective left ventricular lusitropic and venodilatory drug in patients with acutely decompensated heart failure."

Journal • Biosimilar • Heart Failure

Discontinued Drugs for the Treatment of Cardiovascular Disease from 2016 to 2018. (PubMed, Int J Mol Sci) - "Of these, six candidates (MDCO-216, TRV027, ubenimex, sodium nitrite, losmapimod, and bococizumab) were dropped for lack of clinical efficacy, the other six for strategic or unspecified reasons...Four candidate developments (OPC-108459, ONO-4232, GSK-2798745, and TAK-536TCH) were run without biomarkers, which could be used as surrogate endpoints in the 12 cardiovascular drugs discontinued from 2016 to 2018. This review will be useful for those involved in the field of drug discovery and development, and for those interested in the treatment of cardiovascular disease."

Biomarker • Journal • Review